• Portuguese
• English
• Spanish

• Patents
• Copyright
• Trade Secrets & Regulatory
• Data Protection
• Licensing & Technology Transfer
• Internet, E-commerce &Software
• Food & Drug

• Trial associate for biopharmaceutical company in patent enforcement against biosimilar companies
• Associate for startup company in defense of abusive behavior action
• Counsel for pharmaceutical company in an antitrust case involving sham litigation claims.

‍

• IP Stars 2019: Rising star in patents;
• Quinn Emanuel Urquhart & Sullivan, LLP, foreign associate (2017- 2018);
• Stanford Technology Law Review: lead editor; • Hoover IP2 Summer Teaching Institute – Residential Scholarship (2017).

• Trial associate for biopharmaceutical company in patent enforcement against biosimilarcompanies;
• Associate for startup company in defense of abusive behavior action;
• Counsel for pharmaceutical company in an antitrust case involving sham litigation claims.

• Brazilian Bar Association – Rio de Janeiro Section (OAB/RJ).

• Stanford Law School (LLM in Law, Science and Technology 2017);
• Bachelor of Laws (LL.B), Universidade Federal do Rio de Janeiro (2013)

• Co-author: New Regulation of Cannabis-Based Drugs Coming Soon (Update Magazine, a publication of the Food and Drug Law Institute (FDLI), November/December 2019).
• Miller, Shawn P. and Aravind, Ashwin and Bengfort, Bethany and De La Cerda, Clarisse and Dragoni, Matteo and Gibson, Kevin and Itai, Amit and Johnson, Charles and Kannappan, Deepa and Kehoe, Emily and Kim, Hyosang and Mladinich, Katherine and Pinho, Roberto and Polansky, John and Weissenberg, Brian, Who’s Suing Us? Decoding Patent Plaintiffs since 2000 with the Stanford NPE Litigation Dataset (July 18, 2018). Stanford Technology Law Review, Vol. 21, No. 234, 2018.
• Enforcing pending patent applications in Brazil: a different approach to dealing with the backlog (12, 2017 publication descriptionOxford Journal of Intellectual Property Law & Practice)
• Co-author: “Gauging the Future of Biosimilars in Brazil: Looking Ahead after the Approval of the Monoclonal Remsima” (GEN Exclusives, 2015) (http://www.genengnews.com/public/ AnalysisAndInsight/item.aspx?id=77900537&a=false).
• Co-author: “Patent Knowledge Share: Brazil” (The Patent Lawyer Magazine, September/October 2015).
• Co-author: “The Business of Immuno-Oncology” (http://www.genengnews.com/gen-exclusives/ the-business-of-immuno-oncology/77900600).
• Author: “Brazil: Pharmacovigilance Risk in Evolving Biosimilar Regulation” (Update Magazine, a publication of the Food and Drug Law Institute (FDLI), March/April 2015).

‍